Clinical Trials | December 17, 2024
Merck to discontinue KeyVibe and Keyform clinical trials
Merck has also decided to end the favezelimab clinical development program
Merck has also decided to end the favezelimab clinical development program
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
First and only PARP inhibitor to improve overall survival in early breast cancer
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Subscribe To Our Newsletter & Stay Updated
